168.47 USD
+2.05
1.23%
At close Mar 27, 4:00 PM EDT
1 day
1.23%
5 days
0.28%
1 month
-9.52%
3 months
-1.46%
6 months
26.48%
Year to date
-0.06%
1 year
16.60%
5 years
-5.90%
10 years
429.11%
 

About: Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Employees: 3,796

0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

70% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $12.6M

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

28% more capital invested

Capital invested by funds: $6.7B [Q3] → $8.54B (+$1.84B) [Q4]

24% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 50

2.1% more ownership

Funds ownership: 94.6% [Q3] → 96.7% (+2.1%) [Q4]

1% more funds holding

Funds holding: 356 [Q3] → 359 (+3) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 115

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$205
22%
upside
Avg. target
$210
25%
upside
High target
$215
28%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Jason Bednar
36% 1-year accuracy
13 / 36 met price target
28%upside
$215
Overweight
Maintained
26 Feb 2025
Wells Fargo
Vik Chopra
36% 1-year accuracy
4 / 11 met price target
22%upside
$205
Overweight
Maintained
26 Feb 2025

Financial journalist opinion

Based on 13 articles about MASI published over the past 30 days

Positive
Zacks Investment Research
6 days ago
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
1 week ago
3 Reasons Growth Investors Will Love Masimo (MASI)
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love Masimo (MASI)
Neutral
Zacks Investment Research
2 weeks ago
Buy 3 Momentum Anomaly Stocks as Tariffs Take a Toll on Markets
MASI, HOOD and DFS are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Buy 3 Momentum Anomaly Stocks as Tariffs Take a Toll on Markets
Positive
Zacks Investment Research
3 weeks ago
Masimo Corporation (MASI) Hit a 52 Week High, Can the Run Continue?
Masimo (MASI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo Corporation (MASI) Hit a 52 Week High, Can the Run Continue?
Positive
Zacks Investment Research
3 weeks ago
Earnings Estimates Moving Higher for Masimo (MASI): Time to Buy?
Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Moving Higher for Masimo (MASI): Time to Buy?
Positive
Zacks Investment Research
3 weeks ago
Here's Why Masimo (MASI) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Masimo (MASI) is a Strong Momentum Stock
Positive
Zacks Investment Research
3 weeks ago
Here is Why Growth Investors Should Buy Masimo (MASI) Now
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
Here is Why Growth Investors Should Buy Masimo (MASI) Now
Neutral
Business Wire
3 weeks ago
Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 46th Annual Raymond James Institutional Investor Conference on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces.
Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference
Positive
Zacks Investment Research
4 weeks ago
Masimo (MASI) Upgraded to Strong Buy: What Does It Mean for the Stock?
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Masimo (MASI) Upgraded to Strong Buy: What Does It Mean for the Stock?
Positive
Zacks Investment Research
4 weeks ago
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
Charts implemented using Lightweight Charts™